Cyclosporin-induced hypertension in marmosets: a new model of hypertension sensitive to angiotensin-converting enzyme inhibition.
To establish a model of hypertension in marmosets, increasing doses of the immune-modulator cyclosporin (from 3 to 30 mg/kg/day) were given orally to marmosets for 31 days. Cyclosporin consistently induced hypertension with doses greater than or equal to 10 mg/kg/day. Time course and level of hypertension reached were dose-dependent. Hypertension was not associated with an increase of plasma renin activity (PRA) or plasma creatinine concentration and was sensitive to angiotensin-converting enzyme (ACE) inhibition by cilazapril (10 mg/kg p.o.). After cyclosporin treatment was stopped, hypertension regressed. We conclude that hypertension can consistently be induced in marmosets by chronic treatment with cyclosporin.
Clozel
J P
JP
Pharmaceutical Research Department, F. Hoffmann-La Roche & Co., Basel, Switzerland.
Fischli
W
W
D000806:Angiotensin-Converting Enzyme Inhibitors / Q000494:pharmacology*; D000818:Animals; D001794:Blood Pressure / Q000187:drug effects; D002143:Callitrichinae; D017315:Cilazapril; D003404:Creatinine / Q000097:blood; D003524:Cyclosporins / Q000633:toxicity*; D004195:Disease Models, Animal; D005260:Female; D006339:Heart Rate / Q000187:drug effects; D006973:Hypertension / Q000139:chemically induced* / Q000503:physiopathology; D008297:Male; D011724:Pyridazines / Q000494:pharmacology; D013997:Time Factors
D000806:Angiotensin-Converting Enzyme Inhibitors; D003524:Cyclosporins; D011724:Pyridazines; D017315:Cilazapril; D003404:Creatinine